In vitro CYP3A4 Metabolism: Inhibition by Echinacea purpurea and Choice of Substrate for the Evaluation of Herbal Inhibition

被引:21
|
作者
Hansen, Torstein Schroder [1 ]
Nilsen, Odd Georg [1 ]
机构
[1] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, Med Tech Res Ctr, N-7489 Trondheim, Norway
关键词
D O I
10.1111/j.1742-7843.2008.00307.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The in vitro CYP3A4 inhibition profiles of Echinacea purpurea, St. John's wort and ketoconazole were evaluated by three different substrates: 7-benzyloxy-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ) and testosterone. St. John's wort and ketoconazole produced similar inhibition profiles regardless of substrate. For E. purpurea, testosterone metabolism showed a much lower CYP3A4 inhibition (IC50 5394 mu g/ml) compared to the fluorescent substrates BFC and BQ (IC50 354 and 452 mg/ml, respectively). It is suggested that the substrate/assay-dependent effects may arise from a complex nature of E. purpurea constituents, involving different CYP3A4 substrate binding sites. The choice of substrate might thus be essential for evaluation of the inhibition of CYP3A4 metabolism for some herbs. A weak inhibition potential of E. purpurea towards CYP3A4-mediated metabolism in vitro was confirmed by the use of three different substrates.
引用
收藏
页码:445 / 449
页数:5
相关论文
共 50 条
  • [31] Multiplex cell-based assays for the assessment of CYP3A4 induction, metabolism and inhibition
    Trubetskoy, O
    Marks, B
    Printen, J
    Zielinski, T
    Yueh, MF
    Raucy, J
    DRUG METABOLISM REVIEWS, 2004, 36 : 180 - 180
  • [32] Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism
    Kenworthy, KE
    Clarke, SE
    Andrews, J
    Houston, JB
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (12) : 1644 - 1651
  • [33] In vitro inhibition of CYP3A4 by histamine H1 receptor antagonists.
    Hamelin, BA
    Gauvin, C
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PIV30 - PIV30
  • [34] In Vitro Characterization of CYP3A4 Inhibition and Induction of Nevirapine Analogs as Substitutes in HIV Treatment
    Gracey, Emily G.
    Kandel, Sylvie E.
    Lampe, Jed N.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [35] Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data
    Templeton, I.
    Peng, C-C
    Thummel, K. E.
    Davis, C.
    Kunze, K. L.
    Isoherranen, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (04) : 499 - 505
  • [36] Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
    Cardona, Panli
    Dutta, Sandeep
    Houk, Brett
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (07): : 810 - 818
  • [37] Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults
    Boinpally, Ramesh
    Chen, Wayne
    Mcgeeney, Danielle
    Trugman, Joel M.
    PAIN MANAGEMENT, 2023,
  • [38] Safety of Herbal Medicinal Products: Echinacea and Selected Alkylamides Do Not Induce CYP3A4 mRNA Expression
    Modarai, Maryam
    Silva, Elisabete
    Suter, Andy
    Heinrich, Michael
    Kortenkamp, Andreas
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2011, 2011 : 1 - 7
  • [39] Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro
    Han, Mingming
    Zhang, Xiaodan
    Ye, Zhize
    Wang, Jing
    Qian, Jianchang
    Hu, Guoxin
    Cai, Jianping
    CHEMICO-BIOLOGICAL INTERACTIONS, 2021, 350
  • [40] A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
    Fahmi, Odette A.
    Maurer, Tristan S.
    Kish, Mary
    Cardenas, Edwin
    Boldt, Sherri
    Nettleton, David
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (08) : 1698 - 1708